Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

The company will be judged by the results of its peers, and it might not compare as well as shareholders hope.

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

Discover the top gene editing stocks to watch. Learn about this groundbreaking field and the companies leading advancements ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Spread the loveThe world of biotechnology just got a seismic shake-up, and it came from an unexpected corner: artificial intelligence. For years, gene editing has been a frontier of human ingenuity, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's success and management’s execution in ex vivo gene ...

Pioneering gene-editing company CRISPR Therapeutics(NASDAQ: CRSP) was a well-performing biotech stock in August. Its shares were hot in the hot month, zooming almost 19% higher thanks to a solid ...

CRISPR Therapeutics AG (CRSP) closed at $54.23 in the latest trading session, marking a -2.64% move from the prior day. This ...